Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) generates news primarily around its cardiovascular device programs, strategic partnerships and capital markets activity. The company describes itself as a biomedical innovation platform that advances high-impact technologies to patients through collaborations and risk-reward sharing agreements with global medical device companies, which often leads to announcements of new agreements, trial milestones and financial transactions.
News coverage for Orchestra BioMed frequently highlights progress in its two flagship product candidates: Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease. Investors can expect updates on pivotal clinical trials such as the BACKBEAT global study for AVIM Therapy and the Virtue Trial, a U.S. IDE pivotal trial comparing Virtue SAB to a commercially available paclitaxel-coated balloon in coronary in-stent restenosis.
The company’s releases also detail strategic collaborations and rights agreements, including its partnership with Medtronic for AVIM Therapy and a right of first refusal arrangement with Terumo related to Virtue SAB for coronary artery disease. Additional news items describe revenue participation and financing agreements with partners such as Ligand Pharmaceuticals, as well as public offerings, private placements and preferred stock issuances that support its clinical programs.
On this OBIO news page, readers can review company press releases, third-party announcements referencing Orchestra BioMed and regulatory-related communications. Topics typically include clinical data presentations, conference participation, updates on FDA Breakthrough Device Designation status for AVIM Therapy and Virtue SAB, and disclosures of material agreements filed via Form 8-K. Investors and researchers who follow developments in device-based hypertension therapy and drug-delivery balloons for coronary and peripheral artery disease may find this news feed particularly relevant.
Orchestra BioMed (Nasdaq: OBIO) has announced the pricing of a $40 million public offering, consisting of 9,413,637 shares of common stock at $2.75 per share and pre-funded warrants for 5,136,363 shares at $2.7499 per warrant.
The company granted underwriters a 30-day option to purchase up to 2,182,500 additional shares. The offering, expected to close on August 4, 2025, will fund Orchestra's AVIM therapy program, the BACKBEAT study, and the Virtue Sirolimus AngioInfusion Balloon (SAB) program. Piper Sandler and TD Cowen are serving as joint book-running managers for the offering.
Orchestra BioMed (NASDAQ: OBIO) has announced a proposed public offering of common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price.
The proceeds will fund the company's atrioventricular interval modulation (AVIM) therapy program, the BACKBEAT study, and the Virtue Sirolimus AngioInfusion Balloon (SAB) program and trial. Remaining funds will support research, clinical development, and general corporate purposes. Piper Sandler and TD Cowen are serving as joint book-running managers for the offering.
Orchestra BioMed (NASDAQ:OBIO) has secured $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. Ligand will invest $40 million, including $35 million for tiered royalties on AVIM therapy and Virtue SAB sales, plus $5 million in equity. Medtronic will contribute $30 million, comprising $10 million in equity and a $20 million convertible note.
The companies have expanded their collaboration to include development of AVIM therapy-enabled leadless pacemakers. Ligand will receive a low double-digit royalty on the first $100 million in revenues and mid-single-digit royalty on revenues exceeding $100 million. The strategic investment aims to advance Orchestra's technologies targeting hypertension and arterial disease treatments.
Vivasure Medical has announced two significant regulatory milestones for its PerQseal® Elite vascular closure system. The company has submitted a Premarket Approval (PMA) application to the FDA for arterial procedures and received European CE mark approval for expanded indication covering large-bore venous closure.
PerQseal Elite is positioned as the first fully bioresorbable, sutureless solution in Europe for both arterial and venous access closure. The system features a unique inside-vessel deployment mechanism and requires no pre-procedure steps, offering advantages over conventional closure techniques that leave behind materials like collagen, metal implants, or sutures.
Orchestra BioMed (NASDAQ: OBIO) has significantly expanded its intellectual property portfolio for AVIM therapy, securing 10 new patents for hypertension treatment in the past 12 months. The company's global patent estate now totals 137 issued patents, including 120 patents for hypertension and 17 for heart failure treatment, comprising over 2,100 claims. The portfolio includes 46 U.S. patents and 91 international patents across key markets including Europe, Japan, and China.
AVIM therapy recently received FDA Breakthrough Device Designation for treating uncontrolled hypertension in high-risk cardiovascular patients. The therapy is currently being evaluated in the BACKBEAT global pivotal study for treating uncontrolled hypertension in patients with pacemaker indications, targeting a condition that is the leading global risk factor for death and affects millions worldwide.
Orchestra BioMed has received FDA approval for its IDE to start a pivotal U.S. trial of Virtue SAB, its first-in-class Sirolimus-AngioInfusion Balloon. The trial will compare Virtue SAB head-to-head with Boston Scientific's AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis.
Key highlights:
- Virtue SAB is the only non-coated drug-eluting balloon system under clinical investigation worldwide
- The device has received multiple FDA Breakthrough Device Designations
- Trial will involve 740 patients across 75 U.S. centers
- Previous SABRE pilot study showed promising results with 12-month target lesion failure of 2.8%
The trial is set to begin in second half of 2025. Orchestra BioMed aims to tap into a multibillion-dollar U.S. market for coronary drug delivery balloons, with Virtue SAB positioned as a potential new standard of care in interventional cardiology.
Orchestra BioMed (Nasdaq: OBIO) has announced its upcoming participation in several major investor conferences, showcasing its commitment to engaging with institutional investors and sharing company developments.
Key conference appearances include:
- Chardan Capital Conference (April 29, 2025) - CEO David Hochman will join a virtual fireside chat at 10:30am ET discussing "Data & Regulatory Catalysts"
- Jefferies Global Healthcare Conference (June 5, 2025) - Management team will conduct a live fireside chat at 3:45pm ET in New York
- H.C. Wainwright BioConnect Conference (May 20, 2025) - Company will deliver a presentation and host one-on-one investor meetings
All virtual events will be accessible through live webcasts and will remain available on Orchestra BioMed's Investor Relations website after the events. The company, which focuses on accelerating high-impact technologies through risk-reward sharing partnerships, will also offer one-on-one meetings with investors at selected conferences.
Orchestra BioMed (NASDAQ: OBIO) announced a satellite symposium at the HRS 2025 Annual Meeting focusing on their atrioventricular interval modulation (AVIM) therapy program. The FDA recently granted Breakthrough Device Designation for AVIM therapy, targeting patients with uncontrolled hypertension and increased cardiovascular risk.
The symposium, scheduled for April 25, 2025, in San Diego, will feature presentations from leading experts discussing clinical results showing AVIM therapy's effectiveness in reducing systolic blood pressure and improving cardiac function. Orchestra BioMed estimates over 7.7 million U.S. patients meet the criteria for AVIM therapy.
The company is currently enrolling patients in the BACKBEAT global pivotal study in collaboration with Medtronic (NYSE: MDT), evaluating AVIM therapy for uncontrolled hypertension in patients with dual-chamber pacemakers.